Investors holding Scancell (SCLP) have a great deal to weigh up after the Scancell SCLP merger with Neuphoria Therapeutics and a clutch of other developments have shifted the investment case into new territory. The original question, whether SCLP can multiply in value ten times over, has not gone away; it has simply become harder to answer with a lazy yes or no.
What the Scancell SCLP Merger Actually Changes
On 23 July 2026, Scancell announced a merger agreement with Neuphoria Therapeutics, alongside a financing package. Under the terms, Scancell shareholders, together with investors who participated in the associated Private Placement, UK Placing and Retail Offer, are expected to own approximately 86.3% of the combined company’s ordinary share capital on completion, or around 88.9% of total outstanding shares.
Any time a company raises money and admits new investors, existing shareholders face dilution (a reduction in each share’s proportional claim on the business). The 86.3% figure tells you roughly how much of the enlarged entity the existing side retains; the Neuphoria shareholders take the remainder. Whether that split is fair depends on what Neuphoria brings to the table scientifically and strategically, which management will presumably make the case for at the H.C. Wainwright Global Investment Conference on 14–16 September 2026.
The merger financing also includes a non-binding term sheet with funds and accounts managed by BlackRock for up to $25 million (approximately £18.7 million) of debt financing. A non-binding term sheet is not a done deal; it signals intent and outlines terms, but the agreement has not yet been executed. Still, having BlackRock’s name on a term sheet carries weight as a signal of institutional interest in the transaction.
The independent directors, having consulted nominated adviser Panmure Liberum, consider the related-party elements of the merger to be fair and reasonable for shareholders. That is a standard but necessary sign-off for AIM-listed companies undertaking transactions involving related parties.
iSCIB1+: The Science Underpinning the Bull Case
The core asset driving any ten-bagger argument is iSCIB1+, a cancer immunotherapy targeting advanced melanoma. On 19 August 2026, Scancell received Clinical Trial Authorisation from the MHRA (the UK’s Medicines and Healthcare products Regulatory Agency) for a Phase 3 registrational trial of iSCIB1+ in advanced melanoma. A registrational trial is one designed specifically to generate the data needed for a marketing licence; it is the trial that, if successful, leads directly to approval and commercial sales.
The Phase 2 SCOPE study provided the basis for this step. That trial showed a 74% progression-free survival rate at 16 months in advanced melanoma patients, alongside favourable safety data and strong T-cell immune responses. Progression-free survival measures the proportion of patients alive without their disease worsening, so a 74% rate at 16 months is the kind of number that gets regulators interested.
Commercialisation, if the Phase 3 trial succeeds, is targeted for late 2029. That is a three-year runway with plenty of execution risk between here and any revenue. Biotech timelines slip; trials fail; regulatory agencies ask for more data. None of that is unique to Scancell, but it should be factored in alongside the headline figures.
On the market opportunity, a Scancell shareholder circular from November 2023 put the addressable market for unresectable melanoma at $1.5 billion per annum. That is the figure the bulls use to construct a ten-bagger scenario: if iSCIB1+ captures a meaningful slice of a $1.5 billion market, the revenue numbers could justify a substantially higher valuation than the current one. The gap between a clinical-stage valuation and a commercial-stage valuation is where ten-bagger thinking lives, and also where most biotech stories end without the payoff.
Martin Diggle, a Non-Executive Director of Scancell, is closely associated with the Vulpes Testudo Fund, which has been increasing its stake in the company. A key shareholder building their position is one of the inputs bulls point to; it is not a forecast, but it does indicate that at least one informed holder is adding rather than selling.
The MHRA authorisation, the merger financing with BlackRock on the term sheet, and a Phase 3 trial now cleared to begin represent a genuine step-change from the earlier development stage. Whether that step-change is already reflected in the share price, or whether SCLP still has the runway to reward patient holders, comes down to Phase 3 data. Watch for interim readouts and any update on the BlackRock debt facility moving from non-binding to signed.
